A Phase I/II, Open-label, Dose-Escalating Study With a Proof of Concept Cohort to Evaluate the Safety, Tolerability and Efficacy of ARGX-110 in Combination With Azacytidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
Latest Information Update: 11 Aug 2023
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cusatuzumab (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Janssen Research & Development; OncoVerity
- 16 Dec 2022 Status changed from active, no longer recruiting to completed.
- 16 Jun 2022 Planned End Date changed from 15 Oct 2022 to 1 Oct 2022.
- 16 Jun 2022 Planned primary completion date changed from 15 Apr 2022 to 1 Oct 2022.